|
Market Closed -
Nasdaq
21:00:00 11/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 165.18 USD | +0.30% |
|
-1.44% | +0.81% |
| 09-09 | Repligen Corporation Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 01:30 PM | |
| 09-09 | UBS Adjusts Price Target on Repligen to $225 From $195, Keeps Buy Rating | MT |
Company Valuation: Repligen Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 14,643 | 9,401 | 10,039 | 8,064 | 9,224 | 9,322 | - | - |
| Change | - | -35.8% | 6.78% | -19.67% | 14.38% | 1.07% | - | - |
| Enterprise Value (EV) 1 | 14,405 | 9,062 | 9,357 | 7,833 | 9,200 | 9,057 | 8,884 | 8,660 |
| Change | - | -37.09% | 3.26% | -16.29% | 17.46% | -1.55% | -1.91% | -2.52% |
| P/E | 118x | 52.3x | 243x | -313x | 191x | 219x | 95.6x | 68x |
| PBR | 8.67x | 4.92x | 5.09x | 4.09x | 4.38x | 4.27x | 3.98x | 3.61x |
| PEG | - | 1.2x | -3.1x | 2x | -1x | -18.1x | 1x | 1.7x |
| Capitalization / Revenue | 21.8x | 11.7x | 15.7x | 12.7x | 12.5x | 11.3x | 9.57x | 8.14x |
| EV / Revenue | 21.5x | 11.3x | 14.6x | 12.3x | 12.5x | 11x | 9.12x | 7.56x |
| EV / EBITDA | 62.5x | 36.7x | 73.1x | 66.8x | 65.6x | 53x | 40x | 30.1x |
| EV / EBIT | 66.9x | 39x | 99.2x | 95.4x | 90.4x | 69.2x | 50.2x | 35.9x |
| EV / FCF | 277x | 104x | 120x | 52.3x | 98x | 75.1x | 59.4x | 43.5x |
| FCF Yield | 0.36% | 0.96% | 0.83% | 1.91% | 1.02% | 1.33% | 1.68% | 2.3% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 2.24 | 3.24 | 0.74 | -0.46 | 0.86 | 0.756 | 1.728 | 2.429 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 670.5 | 801.5 | 638.8 | 634.4 | 738.3 | 826.9 | 974.4 | 1,145 |
| EBITDA 1 | 230.5 | 246.9 | 128 | 117.3 | 140.3 | 170.9 | 222.1 | 287.7 |
| EBIT 1 | 215.2 | 232.2 | 94.29 | 82.08 | 101.8 | 130.8 | 177 | 241.1 |
| Net income 1 | 128.3 | 186 | 41.58 | -25.51 | 48.89 | 41.92 | 98.84 | 141.2 |
| Net Debt 1 | -237.8 | -339.1 | -681.9 | -231.8 | -23.81 | -264.9 | -438 | -662 |
| Reference price 2 | 264.84 | 169.31 | 179.80 | 143.94 | 163.86 | 165.18 | 165.18 | 165.18 |
| Nbr of stocks (in thousands) | 55,289 | 55,524 | 55,832 | 56,027 | 56,291 | 56,436 | - | - |
| Announcement Date | 17/02/22 | 22/02/23 | 21/02/24 | 20/02/25 | 24/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 218.5x | 10.95x | 53.01x | -.--% | 9.32B | |
| 28.88x | 3.99x | 15.42x | 2.52% | 176B | |
| 19.24x | 3.52x | 12.58x | 3.12% | 116B | |
| 17.61x | 0.2x | 12.86x | 0.74% | 61.36B | |
| 27.83x | 6.83x | 17.6x | 1.44% | 49.42B | |
| 34.27x | 3.34x | 11.43x | 2.21% | 48.44B | |
| 33.28x | 5.85x | 18.35x | -.--% | 31.33B | |
| 42x | 1.24x | 11.46x | 0.22% | 28.56B | |
| 40.38x | 7.07x | 25.37x | 0.26% | 24.37B | |
| 16.74x | 2.67x | 9.46x | 1.65% | 21.57B | |
| Average | 47.87x | 4.57x | 18.75x | 1.22% | 56.71B | |
| Weighted average by Cap. | 30.11x | 3.84x | 15.19x | 1.9% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- RGEN Stock
- Valuation Repligen Corporation
Select your edition
All financial news and data tailored to specific country editions
